Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Navitoclax Plus Ruxolitinib Combo Elicits Responses Indicative of Myelofibrosis Disease Modification

April 12, 2022
By Audrey Sternberg
Article
Conference|American Association for Cancer Research Annual Meeting (AACR)

Bone marrow fibrosis improvement and variant allele frequency reduction observed with navitoclax plus ruxolitinib for patients with previously treated myelofibrosis may suggest disease modification.

The combination of navitoclax plus ruxolitinib (Jakafi) led to an improvement in bone marrow fibrosis (BMF) and reduction in variant allele frequency (VAF) in patients with myelofibrosis (MF) who progressed on or had suboptimal response with prior ruxolitinib monotherapy, according to results of the phase 2 REFINE trial (NCT03222609) that were reported in a poster at the American Association for Cancer Research (AACR) 2022 Annual Meeting.1

Median overall survival (OS) was not reached (NR) in patients who had at least 1 grade improvement in BMF vs those without at 28.5 months (95% CI, 19.6-NR; P <.01). Similarly, median OS was better in those with 20% or greater reduction in VAF vs without (NR vs 28.5 month, respectively; P = .05). No deaths were observed in patients with either BMF improvement or VAF reduction.

“The association of improvements in BMF and VAF with improved overall survival are suggestive of disease modification,” Naveen Pemmaraju, MD, of The University of Texas MD Anderson Cancer Center, and co-authors of this study wrote in their poster. “The navitoclax plus ruxolitinib regimen led to improved outcomes for patients with MF regardless of HMR [high molecular risk] status.”

Despite the ability of ruxolitinib to reduce splenomegaly and constitutional symptoms associated with MF, underlying disease biology typically remains largely unchanged. Roughly half of all patients will discontinue receiving the JAK2 inhibitor after 3 years, with an expectation of poor prognosis following withdrawal of the agent.2,3 Patients with MF who harbor major hydrophilic region (MHR) mutations—such as ASXL1, EZH2, IDH1/2, SRSF2, and U2AF1 Q157—are at increased risk of experiencing leukemic transformation or premature death. Reversed BMF and VAF reduction may be linked with disease modification, but the clinical benefits of these responses have not played out in research.

The multicenter, open-label REFINE study was undertaken to determine if navitoclax with or without rituximab could lead to spleen volume reduction in patients with MF who previously received ruxolitinib monotherapy. The current analysis reports on exploratory outcomes of BMF, VAF, and HMR in patients treated in cohort 1a (n = 34) and how these correlated with efficacy end points. All patients received at least 1 dose of navitoclax starting at 50 mg/day and escalating to 300 mg daily based on tolerability plus ruxolitinib at the patient’s current stable dose. BMF was assessed locally; VAF reduction of the driver gene, either JAK2 or CALR, was assessed centrally by next-generation sequencing in the blood at baseline and 24 weeks.

Of the 32 patients evaluable for BMF, 12 (38%) had at least 1 grade improvement at any time of the study and 4 (13%) experienced a minimum of 2 grade improvements. Additionally, 26 patients were evaluable for driver gene VAF reduction, of whom 19 harbored mutant JAK2 vs 7 with mutant CALR, 6 (23%) had at least a 20% reduction at 24 weeks. Five patients had responses in both BMF and VAF.

Of the patients achieving 35% spleen volume reduction at any time, median OS was not reached in those with improved BMF (n = 9) vs 28.5 months for those without (n = 6; P <.01). Median OS was not reached in either group of patients with (n = 19) or without (n = 14) HRM (P = .45).

In total, 17 patients discontinued navitoclax because of progressive disease (n = 6), adverse effects (n = 5), receipt of transplant (n = 2), death (n = 2), physician decision (n = 1), and degrading quality of life (n = 1). In total, 33 patients had molecular risk information available and 58% were considered to be at HMR. Median follow-up in survivors was 26.2 months (range, 6.7-36.4).

Median patient age was 68 years (range, 42-86), roughly two-thirds (68%) were men, and all participants had an ECOG performance score of either 0 (47%) or 1 (53%). Median duration of prior ruxolitinib exposure was 91 weeks (range, 19-391). The median spleen volume was 1695 cm3 (range, 466-5047). Seventeen patients (52%) had 3 or more mutated genes; 26 patients (79%) presented with mutated JAK2 and 7 (21%) with mutated CALR (type 1, 57% [n = 4]; type 2, 43% [n = 3]). HMR mutations were ASXL1 (68%), SRSF2 (37%), EZH2 (21%), U2AF1 (5%), and IDH1/2 (5%); 42% had mutations in 2 or more HMR genes.

References

  1. Pemmaraju N, Garcia J, Potluri J, et al. Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy. Presented at: American Association for Cancer Research (AACR) 2022 Annual Meeting; April 8-14, 2022; New Orleans, LA. Abstract LB108 / 2.
  2. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053. doi:10.1182/blood-2013-02-485888
  3. Palandri F, Breccia M, Bonifacio M, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020;126(6):1243-1252. doi:10.1002/cncr.32664

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Related Content

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Defining the Role of Immune Therapy in Multiple Myeloma

Roman Fabbricatore
August 19th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 19th 2025
Podcast

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 19th 2025
Article

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 19th 2025
Podcast

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 19th 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 19th 2025
Article
Related Content

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Defining the Role of Immune Therapy in Multiple Myeloma

Roman Fabbricatore
August 19th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 19th 2025
Podcast

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 19th 2025
Article

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
August 19th 2025
Podcast

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 19th 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 19th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.